Hosted on MSN7h
Pfizer Rises 5.6% in a Month: How Should You Play the Stock?Pfizer’s PFE stock has risen 5.6% in the past month. This was due to the company’s encouraging guidance for 2025 issued in ...
PFE's strong economic moat is threatened by upcoming patent expirations, but its oncology segment shows promising growth ...
While the New Year's tradition of drug price hikes has held firm for years, pharma companies have decidedly tamped down on ...
We recently compiled a list of the 15 Stocks Targeted By Activist Hedge Funds. In this article, we are going to take a look ...
Pfizer plans to achieve $4 billion in savings, invest in key areas like oncology and vaccines, and project double-digit EPS ...
At the same time, the expiration of key patents is coming up for some major Pfizer drugs, including blood thinner Eliquis and ...
Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch ...
Pfizer (NYSE:PFE) has entered into a collaborative research agreement with Atavistik Bio for the discovery of novel precision ...
The pharmaceutical industry can be a tough business. Companies must innovate constantly to stay relevant because patents ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback